ABSTRACT
PURPOSE: Pediatric patients with solid tumors treated with prolonged dose-intensive chemoradiotherapy are poor mobilizers of peripheral blood stem cells (PBSC). We have conducted a pilot study to mobilize PBSC in eight pediatric patients with relapsed solid tumors using ifosfamide, carboplatin, and etoposide (ICE) followed-up by IL-11 plus granulocyte colony-stimulating factor (G-CSF). PATIENTS AND METHODS: Patients received ifosfamide 1.8 g/m2 per day for 5 days, carboplatin 400 mg/m2 per day for 2 days, and etoposide 100 mg/m2 per day for 5 days. After completion of ICE chemotherapy, patients received daily subcutaneous injections of G-CSF (5 microg/kg per day) and IL-11 (50-100 microg/kg per day) until peripheral stem cell apheresis. RESULTS: The median age was 11 years. Diagnosis included three relapsed Hodgkin disease, three relapsed central nervous system tumors, one relapsed Wilms tumor, and one relapsed rhabdomyosarcoma. The median number of apheresis procedures required to obtain 5 x 10(6) CD34+ cells/kg was one. The mean +/- standard error of mean (SEM) total CD34+ cells collected was 14.0+/-2.7 x 10(6)/kg. The mean +/- SEM total CD34+/CD41+ cells collected was 4.6+/-1.9 x 10(6)/kg. Seven of the eight patients have subsequently undergone myeloablative chemotherapy with autologous PBSC transplantation and have reconstituted hematopoiesis with a median time to neutrophil recovery of 10 days and platelet recovery of 15.5 days. CONCLUSIONS: We conclude that the regimen of ICE/IL-11 plus G-CSF is successful in mobilizing large numbers of CD34+ PBSC cells with a limited number (one) of apheresis collections in patients that have previously been heavily pretreated with chemotherapy/radiotherapy.
Subject(s)
Bone Marrow Diseases/therapy , Granulocyte Colony-Stimulating Factor/pharmacology , Hematopoietic Stem Cell Mobilization/methods , Hematopoietic Stem Cell Transplantation/methods , Interleukin-11/pharmacology , Neoplasms/therapy , Antineoplastic Combined Chemotherapy Protocols/administration & dosage , Antineoplastic Combined Chemotherapy Protocols/adverse effects , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Blood Cell Count , Bone Marrow Diseases/chemically induced , Carboplatin/administration & dosage , Carboplatin/adverse effects , Child , Child, Preschool , Combined Modality Therapy , Etoposide/administration & dosage , Etoposide/adverse effects , Feasibility Studies , Female , Flow Cytometry , Graft Survival , Humans , Ifosfamide/administration & dosage , Ifosfamide/adverse effects , Male , Neoplasms/blood , Neoplasms/drug therapy , Radiotherapy/adverse effects , Recombinant Proteins/pharmacology , Salvage Therapy , Transplantation ConditioningABSTRACT
We report a 10-year-old male with widespread recurrent Burkitt's lymphoma who underwent successful mismatched unrelated cord blood transplantation (UCBT) following salvage chemotherapy. He was conditioned with TBI, antithymocyte globulin (ATG) and high-dose VP-16 and achieved full donor engraftment. He experienced grade II skin and grade I gastrointestinal acute GVHD with no chronic GVHD. He is alive with no evidence of disease 24 months following UCBT. Bone Marrow Transplantation (2000) 25, 1311-1313.
Subject(s)
Burkitt Lymphoma/therapy , Hematopoietic Stem Cell Transplantation , Burkitt Lymphoma/pathology , Child , Fetal Blood , Humans , Male , Recurrence , Transplantation, HomologousSubject(s)
Adenosine Deaminase/deficiency , Adenosine Deaminase/genetics , Clinical Protocols , Genetic Therapy , Lymphocytes/metabolism , Severe Combined Immunodeficiency/therapy , Antigens, CD34/analysis , Blotting, Southern , Bone Marrow Cells/metabolism , Hematopoietic Stem Cells/metabolism , Humans , Informed Consent , Polymerase Chain Reaction , Prenatal Diagnosis , Retroviridae/metabolism , Transduction, Genetic , Transplantation, AutologousABSTRACT
Untreated patients with Hurler syndrome (MPSIH) experience progressive neurologic deterioration and early death. Allogeneic bone marrow transplantation (BMT) ameliorates or halts this course. The Storage Disease Collaborative Study Group was formed to evaluate the effectiveness and toxicity of BMT. Effectiveness was defined as engrafted survival with continuing cognitive development. Fifty-four patients deficient in leukocyte alpha-L-iduronidase enzyme activity (median age, 1.8 years; range, 0.4 to 7.9) received high-dose chemotherapy with or without irradiation and BMT from HLA-genotypically identical sibling (GIS) or HLA-haploidentical related (HIR) donors between September 16, 1983 and July 14, 1995; all children were included in this report. Thirty-nine of 54 patients (72%) engrafted following the first BMT. The probability of grade II to IV acute graft-versus-host disease (GVHD) at 100 days was 32% for GIS and 55% for HIR patients. The probability of extensive chronic GVHD was 0% for GIS and 24% for HIR patients. The actuarial probability of survival at 5 years was 64% for all patients, 75% for GIS patients, 53% for HIR patients, and 53% for patients with donor marrow engraftment. The baseline Mental Developmental Index (MDI) was examined both for children less than and greater than 24 months of age at BMT. Children transplanted before 24 months had a mean baseline MDI of 78, while those transplanted after 24 months had a mean baseline MDI of 63 (P = . 0002). Both baseline and post-BMT neuropsychologic data were available for 26 of 30 engrafted survivors. Of 14 patients transplanted before 24 months of age, nine demonstrated developmental trajectories that were normal or somewhat slower than normal. In contrast, of 12 patients transplanted after 24 months of age, only three showed developmental trajectories that were normal or somewhat slower than normal (P = .01). For children with a baseline MDI greater than 70, there was a significant correlation between the MDI at follow-up study and leukocyte alpha-L-iduronidase enzyme activity (P = .02). Children were more likely to maintain normal cognitive development if they were fully engrafted following BMT from a donor with homozygous normal leukocyte alpha-L-iduronidase enzyme activity. Children who developed acute GVHD of grade II or worse had significantly poorer cognitive outcomes (P < .009). No difference in the post-BMT MDI was observed between patients whose preparative therapies did (n = 10; radiation dose, 300 to 1,400 cGy) or did not (n = 16) include radiation. We conclude that MPSIH patients, particularly those less than 24 months of age with a baseline MDI greater than 70, can achieve a favorable long-term outcome with continuing cognitive development and prolonged survival after successful BMT from a related donor with homozygous normal enzyme activity.
Subject(s)
Bone Marrow Transplantation , Graft Survival , Mucopolysaccharidosis I/therapy , Child, Preschool , Female , HLA Antigens/immunology , Histocompatibility Testing , Humans , Infant , Male , Mucopolysaccharidosis I/immunology , Mucopolysaccharidosis I/mortality , Survival Analysis , Transplantation, HomologousABSTRACT
Long-term survival and improved neuropsychological function have occurred in selected children with Hurler syndrome (MPS I H) after successful engraftment with genotypically matched sibling bone marrow transplantation (BMT). However, because few children have HLA-identical siblings, the feasibility of unrelated donor (URD) BMT as a vehicle for adoptive enzyme therapy was evaluated in this retrospective study. Forty consecutive children (median, 1.7 years; range, 0.9 to 3.2 years) with MPS I H received high-dose chemotherapy with or without radiation followed by BMT between January 27, 1989 and May 13, 1994. Twenty-five of the 40 patients initially engrafted. An estimated 49% of patients are alive at 2 years, 63% alloengrafted and 37% autoengrafted. The probability of grade II to IV acute graft-versus-host disease (GVHD) was 30%, and the probability of extensive chronic GVHD was 18%. Eleven patients received a second URD BMT because of graft rejection or failure. Of the 20 survivors, 13 children have complete donor engraftment, two children have mixed chimeric grafts, and five children have autologous marrow recovery. The BM cell dose was correlated with both donor engraftment and survival. Thirteen of 27 evaluable patients were engrafted at 1 year following URD BMT. Neither T-lymphocyte depletion (TLD) of the bone marrow nor irradiation appeared to influence the likelihood of engraftment. Ten of 16 patients alive at 1 year who received a BM cell dose greater than or equal to 3.5 x 10(8) cells/kg engrafted, and 62% are estimated to be alive at 3 years. In contrast, only 3 of 11 patients receiving less than 3.5 x 10(8) cells/kg engrafted, and 24% are estimated to be alive at 3 years (P = .05). The mental developmental index (MDI) was assessed before BMT. Both baseline and post-BMT neuropsychological data were available for 11 engrafted survivors. Eight children with a baseline MDI greater than 70 have undergone URD BMT (median age, 1.5 years; range, 1.0 to 2.4 years). Of these, two children have had BMT too recently for developmental follow-up. Of the remaining six, none has shown any decline in age equivalent scores. Four children are acquiring skills at a pace equal to or slightly below their same age peers; two children have shown a plateau in learning or extreme slowing in their learning process. For children with a baseline MDI less than 70 (median age, 2.5 years; range, 0.9 to 2.9 years), post-BMT follow-up indicated that two children have shown deterioration in their developmental skills. The remaining three children are maintaining their skills and are adding to them at a highly variable rate. We conclude that MPS I H patients with a baseline MDI greater than 70 who are engrafted survivors following URD BMT can achieve a favorable long-term outcome and improved cognitive function. Future protocols must address the high risk of graft rejection or failure and the impact of GVHD in this patient population.
Subject(s)
Bone Marrow Transplantation , Mucopolysaccharidosis I/therapy , Bone Marrow Transplantation/adverse effects , Bone Marrow Transplantation/mortality , Bone Marrow Transplantation/statistics & numerical data , Cause of Death , Child, Preschool , Graft Survival , Graft vs Host Disease/etiology , Graft vs Host Disease/mortality , Heart Arrest/etiology , Heart Arrest/mortality , Humans , Iduronidase/blood , Iduronidase/deficiency , Infant , Kidney Failure, Chronic/etiology , Kidney Failure, Chronic/mortality , Life Tables , Lung Diseases/etiology , Lung Diseases/mortality , Mucopolysaccharidosis I/mortality , Mucopolysaccharidosis I/psychology , Neuropsychological Tests , Survival Analysis , Tissue Donors , Transplantation, Homologous , Treatment OutcomeABSTRACT
We investigated the role of thymic function in the immunodeficiency that characterizes bone marrow transplantation (BMT) recipients. The capacity of histocompatible BMT recipients to generate new CD4+ T lymphocytes was determined by FACS analysis with antibodies to the two isoforms of CD45: CD45RA, which is expressed on newly generated CD4 T lymphocytes, and CD45RO, which is expressed on antigen-specific memory CD4 T lymphocytes. Immediately following BMT, all patients had low levels of CD45RA-expressing CD4 T lymphocytes, which increased during the first year and then stabilized. Since thymic function decreases with age in normal individuals, the impact of recipient age on the generation of new CD45RA,CD4 T lymphocytes was determined in BMT recipients with and without chronic graft-vs.-host disease (GVHD). In addition, antigen-specific immune function was determined by assessing in vitro blastogenic response to tetanus toxoid (TT). More than 1 year after transplantation, the results from BMT recipients without chronic GVHD were similar to those of normal individuals; there was an age-dependent decline in the number of CD45RA,CD4 T lymphocytes, and antigen-specific immune function was age-independent. On the other hand, recipients with chronic GVHD had an age-dependent decline in their immune function (r = 0.45 and p = 0.02) that correlated with the number of new CD45RA,CD4 T lymphocytes (p = 0.027) but not the number of memory CD45RO,CD4 T lymphocytes (p = 0.11). Thus recipients with chronic GVHD have decreased antigen-specific immune function that may be due to an acceleration of the normal thymic aging process induced by GVHD and its therapy.
Subject(s)
Bone Marrow Transplantation/immunology , CD4-Positive T-Lymphocytes/immunology , Immunity, Cellular , Immunosuppression Therapy , Thymus Gland/immunology , HumansABSTRACT
Bone marrow transplantation usually entails the ablation of the recipient's immune system. The recovery of immunity after marrow transplantation is a complex process dependent on a number of pre- and posttransplantation factors. Many of the basic concepts of immune reconstitution after transplantation have been elucidated over the past decade. Recent developments focus on attempts to manipulate immune recovery in the posttransplantation period. Soluble mediators of both B-cell and T-cell number and function have been tested in both preclinical and clinical transplant models. The direct administration of T cells after transplantation can be used to augment the immune response to infection, lymphoproliferative disease, and malignancy.
Subject(s)
Bone Marrow Transplantation/immunology , Immune System/physiology , B-Lymphocytes/immunology , Cytokines/physiology , Humans , Lymphokines/physiology , T-Lymphocytes/immunologyABSTRACT
Haematopoietic stem cells in umbilical cord blood are an attractive target for gene therapy of inborn errors of metabolism. Three neonates with severe combined immunodeficiency were treated by retroviral-mediated transduction of the CD34+ cells from their umbilical cord blood with a normal human adenosine deaminase complementary DNA followed by autologous transplantation. The continued presence and expression of the introduced gene in leukocytes from bone marrow and peripheral blood for 18 months demonstrates that umbilical cord blood cells may be genetically modified with retroviral vectors and engrafted in neonates for gene therapy.
Subject(s)
Adenosine Deaminase/deficiency , Adenosine Deaminase/genetics , Antigens, CD34/analysis , Genetic Therapy , Hematopoietic Stem Cell Transplantation , Severe Combined Immunodeficiency/therapy , Adenosine Deaminase/metabolism , Base Sequence , Blood Transfusion, Autologous , Bone Marrow/metabolism , DNA Primers , Female , Fetal Blood , Genetic Vectors , Hematopoietic Stem Cells/enzymology , Hematopoietic Stem Cells/immunology , Humans , Infant, Newborn , Leukocytes/metabolism , Lymphocyte Transfusion , Male , Molecular Sequence Data , Retroviridae/enzymology , Transduction, GeneticABSTRACT
Seven of 21 patients with sickle cell anemia developed neurologic complications 5 to 243 days (median, 33 days) after allogeneic marrow transplantation. Among these 7 patients, indications for transplantation included either a past history of stroke (4 patients) or recurrent severe vaso-occlusive events (3 patients). All received marrow from an HLA-identical sibling after preparation with busulfan and cyclophosphamide, and in 4 patients with antithymocyte globulin. Five of 6 patients developing seizures received anticonvulsant and supportive treatment with resolution of neurologic abnormalities. Three patients experienced intracranial bleeding, which was fatal in two. Of the 14 patients free of neurologic complications, 4 patients had experienced stroke before transplantation. However, among all patients with prior stroke, the incidence of intracranial hemorrhage was 38% (3/8), whereas none of the 13 patients without prior stroke developed posttransplant intracranial bleeding (P = .026). We conclude that patients with sickle cell anemia are at increased risk for neurologic complications after marrow ablative therapy and that patients with prior stroke are at increased risk for intracranial hemorrhage. Transplantation of patients before the onset of overt stroke may reduce this risk.
Subject(s)
Anemia, Sickle Cell/therapy , Bone Marrow Transplantation/adverse effects , Cerebral Hemorrhage/etiology , Seizures/etiology , Adolescent , Adult , Anticonvulsants/therapeutic use , Antilymphocyte Serum/therapeutic use , Busulfan/therapeutic use , Cerebrovascular Disorders/complications , Child , Child, Preschool , Cyclophosphamide/therapeutic use , Female , Histocompatibility Testing , Humans , Male , Seizures/drug therapy , Transplantation, Homologous , Vascular Diseases/complicationsSubject(s)
Adrenoleukodystrophy/therapy , Bone Marrow Transplantation , Central Nervous System Diseases/therapy , Gaucher Disease/therapy , Leukodystrophy, Metachromatic/therapy , Metabolic Diseases/therapy , Mucopolysaccharidoses/therapy , Adenosine Deaminase/deficiency , Child , Humans , Metabolic Diseases/classification , Mucopolysaccharidoses/classification , Osteopetrosis/therapy , Severe Combined Immunodeficiency/therapyABSTRACT
Adenosine deaminase (ADA) deficiency causes severe combined immune deficiency (SCID) by interfering with the metabolism of deoxyadenosine, which is toxic to T lymphocytes at all stages of differentiation. Enzyme replacement with polyethylene glycol-modified ADA (PEG-ADA) has been previously shown to correct deoxyadenosine metabolism and improve mitogen-induced T lymphocyte proliferation. We studied the biochemical and immunologic effects of PEG-ADA in two infants with ADA-deficient SCID. While in a catabolic state, higher doses of PEG-ADA than previously described were required to normalize deoxyadenosine metabolism. After biochemical improvement, the patients recovered immune function in a pattern similar to that observed in normal thymic ontogeny and in patients with immunological reconstitution after bone marrow transplantation. Immune reconstitution was marked by the sequential appearance in the peripheral blood of phenotypic T lymphocytes corresponding to successive stages of thymic differentiation. Functional reconstitution was marked by the successive appearance of mitogen responses dependent on exogenous in vitro IL-2, mitogen responses not requiring exogenous IL-2, antigen-specific responses dependent on exogenous IL-2, and finally, antigen-specific responses not requiring exogenous IL-2. Natural killer function was tested in one patient and normalized with PEG-ADA therapy. Optimal PEG-ADA therapy appears to normalize thymic differentiation in ADA-deficient SCID, resulting in normal antigen-specific immune function.
Subject(s)
Adenosine Deaminase/deficiency , Adenosine Deaminase/therapeutic use , Killer Cells, Natural/immunology , Severe Combined Immunodeficiency/drug therapy , Severe Combined Immunodeficiency/immunology , T-Lymphocytes/immunology , Antigens, CD/blood , Consanguinity , Cytotoxicity, Immunologic , Female , Follow-Up Studies , Humans , Immunophenotyping , Infant , Leukemia, Myelogenous, Chronic, BCR-ABL Positive , Lymphocyte Activation , Middle Aged , Tumor Cells, CulturedABSTRACT
PURPOSE: Cytomegalovirus (CMV) infection remains a major cause of morbidity and mortality after bone marrow transplantation (BMT). Ganciclovir is a guanosine analogue that selectively inhibits CMV DNA polymerase and appears to be a useful agent for BMT patients with CMV pneumonia. One major side effect of ganciclovir is neutropenia, and there may be reluctance to administer ganciclovir to neutropenic patients. However, there is evidence that CMV infection may directly or indirectly cause marrow suppression. In this situation, the potential benefit of ganciclovir may outweigh the risk. PATIENTS AND METHODS: We retrospectively reviewed the charts of 11 consecutive patients receiving ganciclovir for CMV infection posttransplant. A total of 13 courses of ganciclovir were administered. RESULTS: In 10 of 13 cases, the absolute neutrophil count was higher at the completion of ganciclovir therapy than at the start of treatment, including five cases where the absolute neutrophil count was < 500/mm3 at the time ganciclovir was started. In only one of 13 cases was ganciclovir discontinued due to neutropenia. CONCLUSIONS: We conclude that the administration of ganciclovir is not often associated with the development of severe neutropenia in pediatric marrow transplant recipients and that ganciclovir can be safely administered to patients with CMV disease, who are severely neutropenic.
Subject(s)
Bone Marrow Transplantation/adverse effects , Cytomegalovirus Infections/drug therapy , Ganciclovir/adverse effects , Granulocytes/drug effects , Adolescent , Child , Child, Preschool , Female , Ganciclovir/therapeutic use , Humans , Infant , Male , Neutropenia/chemically induced , Retrospective StudiesABSTRACT
The role of allogeneic sibling BMT for children with Wiskott-Aldrich syndrome is established. Mismatched T cell-depleted BMT has been successful, although significant problems with graft rejection, GVHD, and post-transplant lymphoproliferative disorders have been reported. We have performed four BMTs for children with Wiskott-Aldrich syndrome utilizing phenotypically HLA-identical unrelated donors. A non-TBI (total body irradiation) conditioning regimen was utilized, and BM was not T cell-depleted. All patients engrafted and developed significant, although manageable, GVHD. All patients are alive 3+ to 17+ months post-transplant. These results suggest that matched unrelated donor BMT has a definite role in the treatment of Wiskott-Aldrich syndrome.
Subject(s)
Bone Marrow Transplantation , Graft vs Host Disease/drug therapy , Wiskott-Aldrich Syndrome/therapy , Acute Disease , Child, Preschool , Combined Modality Therapy , Graft vs Host Disease/etiology , HLA Antigens , Histocompatibility Testing , Humans , Infant , Male , Treatment Outcome , Wiskott-Aldrich Syndrome/drug therapyABSTRACT
PURPOSE: Bone marrow transplantation usually entails the ablation of the recipient's immune system. The recovery of immunity post-marrow transplantation is a complex process dependent on a number of pre- and posttransplant factors. This knowledge has led to the development of novel approaches to supportive care of the patient, as well as to methods of augmenting immunity. DESIGN: Hematopoietic growth factors are now used to speed neutrophil recovery. Certain lymphokines are being investigated for the enhancement of cell-mediated immunity, and gamma globulin preparations are used to support the deficiency in humoral immunity. CONCLUSIONS: This review summarizes the basic concepts of immune reconstitution posttransplant and discusses some of the therapeutic interventions that have been investigated. In addition, some general recommendations are offered regarding supportive care.
Subject(s)
Bone Marrow Purging/adverse effects , Bone Marrow Transplantation/immunology , Immunologic Deficiency Syndromes/etiology , Lymphokines/therapeutic use , Anti-Infective Agents/therapeutic use , Antigen-Presenting Cells/immunology , B-Lymphocytes/immunology , Hematopoietic Cell Growth Factors/therapeutic use , Humans , Immunization , Immunoglobulins, Intravenous/therapeutic use , Immunologic Deficiency Syndromes/therapy , Immunologic Factors/therapeutic use , Infection Control , Killer Cells, Natural/immunology , Mucous Membrane/immunology , Phagocytosis , Postoperative Care , Skin/immunology , T-Lymphocyte Subsets/immunologyABSTRACT
The Childrens Cancer Study Group evaluated daily oral 13-cis-retinoic acid to determine its therapeutic efficacy in 28 children with advanced neuroblastoma refractory to conventional therapy. Cheilitis and fissured lips were the most common side effects; however, fewer than 50% of the patients experienced any toxicity. Two of twenty-two evaluable children demonstrated positive response to therapy. In one case, a child received the drug for 11 months. Seventeen patients demonstrated progressive disease within 28 days of the start of treatment. Three other patients with stable disease, or removed from study at day 28, were considered nonresponsive. Our data demonstrate that, when given as a single daily oral dose of 100 mg/m2, 13-cis-retinoic acid does not have significant activity in children with advanced neuroblastoma.
Subject(s)
Isotretinoin/therapeutic use , Neuroblastoma/drug therapy , Adolescent , Cheilitis/chemically induced , Child , Child, Preschool , Combined Modality Therapy , Humans , Infant , Isotretinoin/adverse effects , Neuroblastoma/mortality , Remission Induction , Survival RateABSTRACT
Desmoplastic small cell tumors arising diffusely within the abdomen and lacking an apparent organ of origin are rare. Most previously reported cases occurred in children, but young adult patients also have been described. Light microscopic examination shows the tumors to be composed of nests of small cells surrounded by an abundant desmoplastic stroma. Immunohistochemical findings reveal multidirectional differentiation with coexpression of cytokeratin, milk fat globule, neuron-specific enolase, Leu-7, desmin, and vimentin. Electron microscopic examination demonstrates paranuclear condensations of intermediate filaments. The authors describe two patients who died of their disease, despite aggressive chemotherapy and surgical intervention.
Subject(s)
Biomarkers, Tumor , Fibroma/pathology , Peritoneal Neoplasms/pathology , Adolescent , Adult , Desmin/analysis , Histocytochemistry , Humans , Immunoenzyme Techniques , Keratins/analysis , Male , Vimentin/analysisABSTRACT
We performed a retrospective analysis of the incidence, risk factors, and clinical outcome of hepatic veno-occlusive disease (VOD) in 50 children prepared for bone marrow transplantation with busulfan (16 mg/kg) and cyclophosphamide (200 mg/kg). The overall incidence of VOD was 28% (14/50). The incidence of VOD among patients transplanted for leukemia was 36% (14/39). In contrast, no patient transplanted for a genetic disease developed VOD. Neither patient age, sex, remission status, type of graft (i.e. allogeneic or autologous), past history of liver disease nor pretransplant liver function tests were associated with an increased risk of VOD. In addition, 23 of 50 patients had pretransplant samples available for antihepatitis C virus (HCV) testing; 3/23 were reactive (two of nine patients with VOD and one of 14 patients without VOD were positive for anti-HCV). We found a high incidence of pleural effusion in patients with VOD (7/14), an association that has previously not been described. VOD was manageable and resolved in all patients.
Subject(s)
Bone Marrow Transplantation/adverse effects , Busulfan/therapeutic use , Cyclophosphamide/therapeutic use , Hepatic Veno-Occlusive Disease/etiology , Premedication , Adolescent , Adult , Busulfan/adverse effects , Child , Child, Preschool , Cyclophosphamide/adverse effects , Female , Hepatic Veno-Occlusive Disease/chemically induced , Hepatic Veno-Occlusive Disease/epidemiology , Hepatitis C/epidemiology , Humans , Incidence , Infant , Male , Retrospective Studies , Risk FactorsABSTRACT
The first successful allogeneic bone marrow transplants were performed in children with severe combined immune deficiency (SCID). Bone marrow transplants for patients with SCID have been in the forefront of clinical bone marrow transplantation including the first successful use of T lymphocyte-depleted haploidentical bone marrow and matched unrelated donors. Successful bone marrow transplantation for most forms of SCID requires only the engraftment of donor lymphoid stem cells; donor hematopoietic stem cell engraftment is usually not required. The Wiskott-Aldrich syndrome was the first genetic disease involving the hematopoietic stem cell to be completely corrected by allogeneic bone marrow transplantation. The successful transplantation of Wiskott-Aldrich syndrome patients demonstrated that agents with adequate anti-lymphoid and hematopoietic stem cell activity were necessary in order to achieve complete donor lymphoid and hematopoietic stem cell engraftment. Initially, total body irradiation and now busulfan are used to ablate recipient hematopoietic stem cells, while cyclophosphamide is used to ablate recipient lymphoid stem cells. No single agent/drug is capable of eliminating both stem cell populations. Histocompatible bone marrow transplantation has a role in the treatment of patients with immune deficiency due to primary defects of the hematopoietic stem cell. The recent introduction of cytokines (gamma-interferon and granulocyte colony stimulating factor) may reduce the need for bone marrow transplantation for myeloid immune deficiency states. Initial attempts to treat patients with the acquired immune deficiency syndrome by bone marrow transplantation were limited by the lack of effective concomitant anti-viral therapy. Bone marrow transplantation for immune deficiency states continues to be in the forefront of human bone marrow transplantation.
Subject(s)
Bone Marrow Transplantation , Immunologic Deficiency Syndromes/surgery , Acquired Immunodeficiency Syndrome/surgery , Bone Marrow Transplantation/adverse effects , Bone Marrow Transplantation/immunology , Bone Marrow Transplantation/methods , Graft Rejection , Graft vs Host Disease/complications , Granulomatous Disease, Chronic/surgery , Herpesvirus 4, Human , Histocompatibility , Humans , Immunosuppression Therapy/adverse effects , Lymphoma, Non-Hodgkin/etiology , Preoperative Care/methods , T-Lymphocytes/immunology , Wiskott-Aldrich Syndrome/surgeryABSTRACT
Although autologous bone marrow transplantation (ABMT) following purging with 4-hydroperoxycyclophosphamide (4HC) has been effective for some adults with acute non-lymphoblastic leukemia (ANLL), there are few data on ABMT for children. We have performed ABMT for 13 patients (median age, 5 years) with ANLL in second remission. Bone marrow was treated ex vivo with 4HC to kill residual leukemic cells. In order to enhance the anti-leukemic effect of 4HC, exogenous red blood cells were eliminated from the marrow/4HC mixture. All patients were conditioned for transplantation with busulfan (16 mg/kg) and cyclophosphamide (200 mg/kg), followed by infusion of the 4HC treated marrow. Eleven of 13 patients had complete hematologic reconstitution; there were no transplant-related deaths. Five patients relapsed at 2, 4, 5, 6 and 6 months post-BMT. Eight patients are disease-free survivors; the median time for survival is 24 months, with a projected disease-free survival of 61%. ABMT is a safe and efficacious treatment modality for children with ANLL in second remission. Our results suggest that the disease-free survival for pediatric patients may be superior to that seen in adults.
Subject(s)
Bone Marrow Transplantation , Cyclophosphamide/analogs & derivatives , Leukemia, Myeloid, Acute/surgery , Neoplastic Stem Cells/drug effects , Actuarial Analysis , Adolescent , Adult , Bone Marrow Transplantation/methods , Busulfan/administration & dosage , Child , Child, Preschool , Cyclophosphamide/administration & dosage , Cyclophosphamide/pharmacology , Cyclophosphamide/therapeutic use , Evaluation Studies as Topic , Graft Survival , Humans , Infant , Leukemia, Myeloid, Acute/pathology , Remission Induction , Transplantation, AutologousABSTRACT
Bone marrow transplantation is the treatment of choice for a number of genetic diseases. Recently, bone marrow transplantation has been increasingly used for erythroid disorders, such as thalassemia and sickle cell anemia. A number of inherited metabolic disorders (i.e., storage diseases, leukodystrophies, and the like) may be corrected with a marrow transplant. Successful correction of genetic diseases with allogeneic bone marrow transplantation lays the groundwork for the use of specific gene therapy.